Network News

X My Profile
View More Activity
Column Archive |  On Twitter: J Huget and MisFits  |  Fitness & Nutrition News  |  RSS Feeds RSS Feed
Posted at 12:01 AM ET, 11/22/2010

New embryonic stem cell experiment

By Rob Stein

Government regulators have given the go-ahead to a second study that will for the first time carefully test a treatment created using human embryonic stem cells in people, according to the company sponsoring the experiment.

The Food and Drug Administration approved a request by Advanced Cell Technology Inc. of Marlborough, Mass., to inject cells created from human embryonic stem cells into the eyes of 12 patients suffering from advanced cases of a disease that causes blindness.

Stargardt's Macular Dystrophy, which is one of the most common forms of juvenile macular blindness, progressively destroys vision, usually beginning in childhood. It is currently incurable.

The study will involve injecting 50,000 to 200,000 cells known as retinal pigmented epithelial cells in the hopes that they will replace those ravaged by the disease. Studies in rats found the cells helped prevent further vision loss and even restored some sight. While the study is designed primarily to test the safety of the treatment, researchers will looks for signs of improvement in the patients' vision. The company hopes the approach will work for many conditions, including the leading cause of blindness among the elderly.

"I think this marks the beginning of a new era for stem cell research," Robert Lanza, the company's chief scientific officer, wrote in an email. "After a decade of intense controversy, the field is finally ready to prove itself--and to actually start helping patients suffering from a range of horrific diseases. It also shows the new readiness of the FDA to work with researchers to move exciting new stem cell therapies out of the laboratory and into the clinic."

The study will be conducted at the Casey Eye Institute in Portland, Ore., and University of Massachusetts Memorial Medical Center in Worcester, and the University of Medicine & Dentistry of New Jersey in Newark.


An embryologist places human embryos onto a petri dish. (Photo by Sandy Huffaker/Bloomberg via Getty Images)

The approval follows a decision by the FDA in July to authorize the first carefully designed study testing a therapy created using human embryonic stem cells in humans. That study, being sponsored by Geron Corp. of Menlo Park, Calif., will involve 10 patients partially paralyzed by a spinal cord injury in the previous one to two weeks. Patients are receiving millions of "oligodendrocyte progenitor cells" created from embryonic stem cells in the hopes the cells will form a restorative coating around the damaged spinal cord. In tests in hundreds of rats, partially paralyzed animals regained movement. The first patient to get the therapy as part of the trial was treated in October in Atlanta and is now being monitored closely.

The studies are being welcomed by many stem cell researchers, patients and advocacy groups. But those with moral objections to any research using cells from human embryos object to the study. And the tests are worrying some proponents of the research. Some argue that the experiments are premature. Others question whether they are ethical. Many fear that the trials risk disaster for the field if anything goes wrong.

The studies are beginning as the future of federal funding for human embryonic stem cell remains uncertain. A federal judge ruled in August that the Obama administration's new, more permissive guidelines violated a federal law barring taxypayer money from being used for research that involves the destruction of human embryos. The administration appealed, and an appeals court panel in September allowed the funding to continue while the case is argued in court.

By Rob Stein  | November 22, 2010; 12:01 AM ET
Categories:  FDA, Stem cells  
Save & Share:  Send E-mail   Facebook   Twitter   Digg   Yahoo Buzz   Del.icio.us   StumbleUpon   Technorati   Google Buzz   Previous: Painkiller Darvon pulled because of risk to heart
Next: Thanksgiving's slippery slope

Comments

I for one am thrilled to see this testing beginning, there are such exciting possibilities. I hope this is allowed to continue.

Posted by: honeybnutrition | November 22, 2010 7:58 AM | Report abuse

Great news. We have been following this story this year on my lab's blog and have a lot of background as well as our take on this news.

http://www.ipscell.com

Paul

Posted by: ipscell | November 22, 2010 12:21 PM | Report abuse

Gradually, with agonizing slowness, society is beginning to reject mere belief as a guide to human behaviour. Belief, whether sacred or secular, should never be allowed to replace objective fact in the making of law.

Now if only we might demand an educational system that teaches our children to tell the difference between knowledge and belief . . . .

Posted by: dunkberg | November 22, 2010 2:23 PM | Report abuse

Post a Comment

We encourage users to analyze, comment on and even challenge washingtonpost.com's articles, blogs, reviews and multimedia features.

User reviews and comments that include profanity or personal attacks or other inappropriate comments or material will be removed from the site. Additionally, entries that are unsigned or contain "signatures" by someone other than the actual author will be removed. Finally, we will take steps to block users who violate any of our posting standards, terms of use or privacy policies or any other policies governing this site. Please review the full rules governing commentaries and discussions.




characters remaining

 
 
RSS Feed
Subscribe to The Post

© 2010 The Washington Post Company